Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Upadacitinib in Elderly Patients with Inflammatory Bowel Disease: Multicenter Real-World Cohort
ChiCTR2500113468Phase 4Not yet recruiting
- Sponsor
- Union Hospital
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of upadacitinib in inflammatory bowel disease (IBD), autoimmune colitis and Crohn's disease (2 cohorts), sponsored by Union Hospital. Primary endpoint: Clinical remission rate at end of induction. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
upadacitinib
03
Conditions
inflammatory bowel disease (IBD)autoimmune colitisCrohn's disease
Beyond the preview
Go deeper on ChiCTR2500113468.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500113468.